" class="no-js "lang="en-US"> Kåre Engkilde - Medtech Alert
Friday, September 26, 2025
Kåre Engkilde

Kåre Engkilde

About Kåre Engkilde

Fast-track life science leader with reputation for effectively managing stakeholders by initiating and launching mutually beneficial collaborations. Experience spans all phases of life science, from idea, to concept, to R&D, to attracting investors and identifying patents. I’m entrepreneurial, success-driven, and “can-do” person.

I have navigated political and siloed environments, made hard calls, and improved overall quality.

KEY SKILLS:
★ Business acumen combined with scientific excellence.
★ Re-focus companies to gain traction.
★ Execute operational and strategic leadership in both small and large organizations.

BACKGROUND:
PhD who
– Visited (postdoc work) Professor Vipin Kumar, Torrey Pines Institute for Molecular Studies, San Diego, USA
– Visited (postdoc work) Professor Ann-Therese Karlberg, Department of Chemistry, University of Gothenburg, Sweden

PUBLICATIONS
►29 peer-reviewed articles (PubMed)

GRANTS/AWARDS
►Co-secured double-digit MDKK grant, Denmark, 2016
►2.5 MDKK postdoc scholarship, Region Hovedstaden, Denmark, 2009
►3-year postdoc scholarship, Danish Diabetes Academy, Denmark, 2011

SPECIALTIES
• Leadership • Project Management • Stakeholder Management • R&D Strategy • Pharmaceuticals • Medical Devices • In Vitro Diagnostics • Advanced Therapy Medical Products • Clinical Development • Biotechnology • Immunology • Inflammation • Biotechnology
___________________________________

Related Story

Amniotics AB Announces Positive Pre-clinical Proof-of-concept Results for PulmoStem™ in End-stage Lung Disease

April 29 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that PulmoStem™ significantly reduces the incidence of […]

Amniotics Receives Approval for Phase I/II Study of Pulmostem™ in Hospitalized COVID-19 Patients

April 6 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received approval by regulatory […]

Amniotics Strengthens its Clinical and Regulatory Capabilities

January 25 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, has appointed […]

Amniotics Secures Funding of SEK 4,8 Million from Vinnova to Develop Stem Cell Therapies

January 20 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received a non-diluting grant […]

Amniotics Joins Vinnova Funded ’CAMP’ to Improve Outcome of Lung Transplantations with PulmoStem™

December 21 2021

Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, today announced that […]

Stem Cell Therapy Company Amniotics Raises SEK 60 Million

July 13 2021

Amniotics AB (publ) (“Amniotics” or the “Company”), a stem cell therapy company has raised SEK60 million through […]